On Friday, October 13, 2023, our Managing Director Ms. Jennifer Che participated as a panelist in InvestHK’s event “Unlock the Life & Health Sciences Potential through Innovation”. Keynote speeches focused on Hong Kong’s strengths in the life sciences (good medical schools, strong research) and also Hong Kong’s challenges bridging the gap between fundamental research and commercial products. The panel discussion centered around “Hong Kong as a life and health technology innovation hub.” Moderated by Dr. Josephine Au from InvestHK, the other panel members included Ir. Eric Chan from Hong Kong Cyberport Management Co. Ltd., Dr. Grace Lau from HKSTP Institute of Translational Research, Ms. Simone Song from ORI Capital and Mr. Henry Yau from HKU Clinical Trials Centre. Jennifer shared about Hong Kong’s uniqueness as a place to find IP experts having international qualifications as well as cross-border experience. She also expressed frustration at how many HK companies still don’t value the importance of good IP strategy (and are unwilling to invest in such matters), which hurts them when they enter the international stage down the road. It was an enlightening discussion and valuable to hear various people’s thoughts on the future of Hong Kong in the life & health sciences area.
Our Past Events
Recommended Insights
Beijing IP Court Reverses CNIPA Decision and Upholds Ozempic® semaglutide patent in China as VALID based on Novo Nordisk’s Post Filing Data
27 June 2024Recently, all eyes have been on China as the fundamental patent covering semaglutide, the active ingredient in Ozempic® and Wegovy®, will expire on March 20, 2026. It goes without saying that generics are ramping up bigtime in China (and also around the world), preparing to manufacture and sell this blockbuster drug to one of the […]
Read more >
Can I transfer priority rights in China without the consent of other applicants? Insights from the Broad Institute’s CRISPR patent
4 February 2025The high-profile disputes surrounding an important CRISPR patent belonging to The Broad Institute, MIT and Harvard (hereinafter “the proprietors”) has attracted a lot of attention in recent years, particularly regarding the validity of priority rights that were challenged worldwide. In Europe, the patent was famously revoked by the European Patent Office (hereinafter “EPO”) due to […]
Read more >
China Finally Clamps Down on Facial Recognition Technology
24 August 2021Snippets of Court Cases, Provisions, and Key Observations about China’s IP Landscape Around the end of July 2021, the Supreme People’s Court issued a new Provision concerning the application of law about a super-hot technology, facial recognition. This Provision is a legal explanation from the SPC explaining how the law should be applied or interpreted […]
Read more >
Burden Shift: CNIPA Requires Applicant to “Prove” that Post-Filing Data is not Fake Data
1 April 2025“Good Faith” is a challenging concept that brings with it the nuances of a particular jurisdiction’s ideas about honesty, moral values, and societal expectations. Most patent laws around the world include good faith requirements – especially in matters involving the legal and the medical profession – and China is no exception. So what’s the standard? […]
Read more >